Related Experiment Video
Updated: Jan 17, 2026

08:23
A Multimodal Imaging- and Stimulation-based Method of Evaluating Connectivity-related Brain Excitability in Patients with Epilepsy
Published on: November 13, 2016
11.7K
Interpretable Transformer Models for rs-fMRI Epilepsy Classification and Biomarker Discovery
Medrxiv : the Preprint Server for Health Sciences
|September 15, 2025
Summary
A novel regularized transformer model effectively classifies epilepsy using resting-state fMRI (rs-fMRI) data, identifying potential network biomarkers for diagnosis. Further validation is needed for clinical application.
Area of Science:
- Neuroimaging
- Artificial Intelligence
- Medical Diagnostics
Background:
- Automated interpretation of resting-state fMRI (rs-fMRI) for epilepsy diagnosis is challenging.
- Developing robust methods for classifying epilepsy using rs-fMRI is crucial for improving patient outcomes.
Purpose of the Study:
- To develop and evaluate a regularized transformer model for epilepsy classification using rs-fMRI.
- To identify interpretable, network-level candidate biomarkers for epilepsy.
Main Methods:
- Utilized Schaefer-200 parcel time series from rs-fMRI data preprocessed with fMRIPrep.
- Developed a regularized transformer model incorporating attention mechanisms, learned positional encoding, and fMRI-specific regularization.
- Trained and validated the model using 4-fold cross-validation on a cohort of 65 participants (30 epilepsy, 35 controls) and an independent external dataset.
Main Results:
- The regularized transformer achieved high performance in within-fold classification (e.g., Accuracy 0.77, AUC 0.76).
- External validation showed promising but lower performance (Accuracy 0.60, AUC 0.64).
- Attribution-guided analysis identified candidate biomarkers in limbic, somatomotor, default-mode, and salience networks.
Conclusions:
- A regularized transformer model shows potential for classifying epilepsy from rs-fMRI and generating interpretable biomarkers.
- Preliminary results suggest the model's efficacy, but larger multi-site validation and stability testing are necessary for clinical translation.

